Supplementary Data Table 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
收藏Figshare2025-01-13 更新2026-04-28 收录
下载链接：
https://figshare.com/articles/dataset/Supplementary_Data_Table_1_from_Zongertinib_BI_1810631_an_Irreversible_HER2_TKI_Spares_EGFR_Signaling_and_Improves_Therapeutic_Response_in_Preclinical_Models_and_Patients_with_HER2-Driven_Cancers/28193748
下载链接
链接失效反馈官方服务：
资源简介：
MANO method and results. Sheet 1: Primer sequence for the bar code amplification. Sheet 2: Primer sequence for next-generation sequencing analysis. Sheet 3: Raw data for zongertinib (BI 1810631 in table) drug sensitivity assay.
创建时间：
2025-01-13
